Oncimmune Set For Bigger US Push Of Early-Stage Lung Cancer Test
Executive Summary
Oncimmune Ltd. is seeking new distribution partners in the US as it expands commercialization of its a one-of-a-kind immunoassay for early-stage lung cancer that can detect circulating antibodies in the blood of patients with lung cancer up to four years before standard imaging tests. Positive interim data from a UK randomized clinical trial is expected to help fuel uptake of the test.
You may also be interested in...
Market Intel: Can New Wave Of Tests Finally Nail Early Diagnosis Of Lung Cancer?
Early diagnosis of lung cancer continues to be a major clinical challenge and the opportunity for products that can successfully detect the disease early enough to boost survival rate is huge. This article looks into the market potential and highlights companies developing technologies that they believe can finally turn this deadliest of cancers on its head.
Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
FDA’s International Harmonization Plan Points To Ongoing Priorities
A new draft global harmonization plan from the device center at the US Food and Drug Administration may not contain any surprises, but it does highlight increasing agency engagement with international bodies.